Followers | 145 |
Posts | 27566 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, November 23, 2021 7:59:17 AM
November 23 2021 - 04:11AM
RBC Capital analyst Gregory Renza maintained a Buy rating on Gamida Cell (GMDA – Research Report) on November 15 and set a price target of $10.00. The company's shares closed last Monday at $2.78, close to its 52-week low of $2.75. According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.1% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Inovio Pharmaceuticals. Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.50, which is a 389.9% upside from current levels.
https://www.tipranks.com/news/blurbs/rbc-capital-thinks-gamida-cells-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Recent GMDAQ News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:19:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/09/2024 08:08:28 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/09/2024 08:04:39 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM